ScreenerHero

HCWBHCW Biologics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · hcwbiologics.com
2.180USD-5.22%Mkt Cap: 4.00M $P/E: —

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products includ…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap4.00M $
Enterprise Value8.36M $
Revenue (TTM)6.59M $
Gross Profit10.85K $
Net Income (TTM)-7.96M $
Revenue/Share12.46 USD
Last Price2.180 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees35
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.85
PEG—
EV/EBITDA-1.47
EV/Revenue1.27
P/S0.59
P/B0.42
EPS (TTM)-15.06
EPS (Forward)-0.55
52W Range
1.5002% of range44.10
52W High44.10 USD
52W Low1.500 USD
Profitability
Gross Margin20.00%
Oper. Margin49.45%
EBITDA Margin-86.41%
Profit Margin-14677.14%
ROE-287.90%
ROA-32.46%
Growth
Revenue Growth129080.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.39M $
CapEx (TTM)—
FCF Margin-158.34%
FCF Yield-260.75%
Net Debt5.35M $
Net Debt/EBITDA-0.94
Balance Sheet
Debt/Equity2.46
Current Ratio0.09
Quick Ratio0.07
Book Value/Sh5.058 USD
Cash/Share1.095 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:6
Split DateJun 30, 2026
Analyst Consensus
Rating—
Target (Mean)30.00 USD
Upside (mean)+1276.1%
Target Range30.00 USD – 30.00 USD
# Analysts1
Ownership
Shares Out.1.84M
Float946.94K
Insiders10.70%
Institutions8.21%
Short Interest
Short Ratio0.3d
Short % Float1.40%
Short % Out.1.31%
Shares Short20.98K
Short (prev mo.)41.71K
Technical
SMA 504.357 (-50.0%)
SMA 2006.597 (-67.0%)
Beta2.36
S&P 52W Chg18.16%
Avg Vol (30d)67.14K
Avg Vol (10d)185.27K
Technical Indicators
RSI (14)26.8
MACD-0.5511
MACD Signal-0.5600
MACD Hist.+0.0089
BB Upper3.787 USD
BB Middle2.946 USD
BB Lower2.105 USD
BB Width57.10%
ATR (14)0.4881 USD
Vol Ratio (20d)0.74x